Glaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
Follow GKOS
Alert me
Glaukos Corporation (GKOS) P/S ratio
As of 5 November 2026, Glaukos Corporation (GKOS) trades at a P/S ratio of 18.8×. Over the past ten years it has ranged from 1.1× (September 2015) to 23.3× (December 2024); the current reading is higher than 95% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 12.7× | (38.31%) |
| FY2024 | 20.6× | 73.89% |
| FY2023 | 11.9× | 61.18% |
| FY2022 | 7.4× | 4.89% |
| FY2021 | 7.0× | (52.86%) |
| FY2020 | 14.9× | 73.38% |
| FY2019 | 8.6× | (21.54%) |
| FY2018 | 10.9× | 87.18% |
| FY2017 | 5.8× | (39.77%) |
| FY2016 | 9.7× | 61.30% |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 14.1× | 4.80% |
| Jun 2026 | 13.4× | 18.39% |
| Mar 2026 | 11.3× | (10.97%) |
| Dec 2025 | 12.7× | 27.72% |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 1.4× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 2.4× |
| BRKR Bruker Corporation compare | 2.5× |
| PODD Insulet Corporation compare | 3.4× |
| GMED Globus Medical, Inc. compare | 3.5× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.8× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.9× |
| PEN Penumbra, Inc. compare | 8.1× |
| GKOS Glaukos Corporation | 18.8× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on GKOS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement